COVID-19testing and vaccinationsocialnetworkdiffusion for diversecriminallegalinvolvedcommunities
Project Number1U01MD017414-01
Former Number1U01MH129918-01
Contact PI/Project LeaderSCHNEIDER, JOHN Other PIs
Awardee OrganizationUNIVERSITY OF CHICAGO
Description
Abstract Text
Abstract: This RADx-UP Phase II proposal, “Socialnetworkdiffusion of COVID-19 prevention for diverseCriminalLegalInvolvedCommunities”, will implement a situation appropriate COVID-19testing and
vaccinationsocialnetworkdiffusion intervention – C3 – building upon RADx-UP Phase I lessons and
successful socialnetwork prevention interventions developed previously by the research team. C3 CriminalLegalInvolved (CLI) populations encompass those non-incarcerated who have experienced recent arrest,
incarceration, probation, parole or diversion programs such as drug courts. While increases in COVID-19testing have been observed among this group, there remain members with limited testing history as well as
individuals who are vaccine hesitant. COVID-19 prevention messaging can no longer be simplified to
“everyone test and/or everyone vaccinate” as testing and vaccination decisions among community members
are sensitive to personal histories (i.e., prior infection), local infection rates (i.e., low rates) and
testing/vaccination availability. As COVID-19 prevention efforts have become more complicated (i.e., test if
exposed), people tend to focus on the messenger, and particularly those that are close to them. Personal
connections and communications within existing personal network structures, such as families, friends and
other trusted acquaintances represent the cornerstone to increase situation appropriate testing and
overcoming COVID-19 vaccine hesitancy. C3 builds upon RADx-UP I, by using a networkdiffusion approach
facilitated through motivational interviewing purposefully geared to mobilize one’s own organic socialnetwork
to increase context appropriate testing and vaccine uptake. Through this process we will maximize the primary
benefit and impact of this type of intervention which also has the intended effect of increasing likelihood that
the messenger themselves will undergo the same behavior change that they have been trained to promote.
We will leverage infrastructure developed in RADx-UP Phase I, which includes 4 high-impact sites across the
Central US from Phase I: Baton Rouge LA, Little Rock AR, Indianapolis IN, and Chicago IL. We will utilize
established engagement efforts already in place and continue to fully integrate communities in the strategic
application of the intervention. We will use the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and
Maintenance) framework to guide implementation. C3 aims to: Aim 1a. Test the efficacy (3-month situation
appropriate testing or vaccination) of a networkdiffusion intervention (C3) versus an existing COVID-19testing
and vaccine linkage to care intervention among: 1) primary study participants (primary outcome); and 2)
secondary study participants connected to primary participants (secondary outcome) using a RCT design. Aim
1b. Explore the mechanisms for differential intervention effects at the individual and network-level that may
increase situation appropriate testing and/or vaccination uptake. Aim 2. Examine key RE-AIM components in
real time tied to the implementation of the networkdiffusion intervention (C3).
Public Health Relevance Statement
Narrative: This RADx-UP Phase II proposal, “Socialnetworkdiffusion of COVID-19 prevention for diverseCriminalLegalInvolved (CLI) Communities”, will implement a situation appropriate COVID-19testing and
vaccinationsocialnetworkdiffusion intervention. COVID-19 prevention messaging can no longer be simplified
to “everyone test and/or everyone vaccinate” as testing and vaccination decisions among community members
are sensitive to personal histories (i.e., prior infection), local infection rates (i.e., low rates) and
testing/vaccination availability. We build upon RADx-UP Phase I, by using a networkdiffusion approach
facilitated through motivational interviewing purposefully geared to mobilize one’s own organic socialnetwork
to increase situation appropriate testing and vaccine uptake.
National Institute on Minority Health and Health Disparities
CFDA Code
310
DUNS Number
005421136
UEI
ZUE9HKT2CLC9
Project Start Date
01-January-2022
Project End Date
30-November-2023
Budget Start Date
01-January-2022
Budget End Date
30-November-2022
Project Funding Information for 2022
Total Funding
$1,226,130
Direct Costs
$902,844
Indirect Costs
$323,286
Year
Funding IC
FY Total Cost by IC
2022
NIH Office of the Director
$1,226,130
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U01MD017414-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U01MD017414-01
Patents
No Patents information available for 1U01MD017414-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U01MD017414-01
Clinical Studies
No Clinical Studies information available for 1U01MD017414-01
News and More
Related News Releases
No news release information available for 1U01MD017414-01
History
No Historical information available for 1U01MD017414-01
Similar Projects
No Similar Projects information available for 1U01MD017414-01